Prevalence of HIV and Tuberculosis in Masiphumelele Township, Cape Town, South Africa
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130305101310im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this study is to estimate the amount of HIV and tuberculosis (TB) infection in individuals 15 years and older in the Masiphumelele township of Cape Town, South Africa. Data collected in this study will be used to predict the effect of introducing anti-HIV therapy in this community.
Condition |
---|
HIV Infections Tuberculosis |
Study Type: | Observational |
Study Design: | Observational Model: Ecologic or Community Time Perspective: Prospective |
Official Title: | Protocol for Cross-Sectional Survey of Acid-Fast Bacilli (AFB) Smear Positive and/or Culture Positive Tuberculosis in the Masiphumelele Township |
- Number of Participants With Microbiologically Confirmed Pulmonary Tuberculosis [ Time Frame: Pulmonary Tuberculosis diagnosed from sputum sample obtained at the study visit ] [ Designated as safety issue: No ]Confirmed Pulmonary Tuberculosis based on the sputum smear and culture results. The sputum sample was obtained at the once off study visit.
- Number of Participants With a Positive HIV Test [ Time Frame: HIV status at the time of the study visit ] [ Designated as safety issue: No ]Prevalence of HIV in the community based on a positive oral mucosal transudate sample obtained at the once off study visit.
Biospecimen Retention: Samples With DNA
Sputum samples
Enrollment: | 762 |
Study Start Date: | February 2005 |
Study Completion Date: | February 2006 |
Primary Completion Date: | August 2005 (Final data collection date for primary outcome measure) |
TB is the most common opportunistic infection among HIV infected people, and is the most common cause of death in HIV infected people in Africa. The Masiphumelele township of Cape Town, South Africa, with its high rates of TB and HIV, is representative of many poor communities of Africa. Via random sampling, this study will assess the prevalence of HIV and TB infections in the Masiphumelele township. Knowledge gained from this study will be used to predict if introducing antiretroviral therapy will reduce the prevalence of TB in this community.
Selection and enrollment of participants will last about 4 months. Potential participants will be visited in their homes by fieldworkers, who will explain the study. Participants will be invited to either go to the clinic on the day of the fieldworker's visit or to go on a different day. Participants who go to the clinic on the day of the visit will have two sputum samples collected with a nebulizer. Participants who do not go to the clinic on the visit day will be given a sputum sample bottle and will be asked to collect a sputum sample in the early morning the day before their clinic appointment. At the clinic appointment, another sputum sample will be collected from these participants. Direct smear acid-fast bacilli and Mycobacterium tuberculosis cultures will be done on both sputum samples. Participants who test positive for TB will be referred for TB treatment at the clinic. Participants will also be asked to complete a study questionnaire and will undergo an anonymous oral HIV test at the clinic visit.
![](https://webarchive.library.unt.edu/web/20130305101310im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Residents of the Masiphumelele township of Cape Town, South Africa
Inclusion Criteria:
- Resident of the Masiphumelele township for at least 1 week prior to study entry
- Willing to provide informed consent
- Willing to comply with study requirements
![](https://webarchive.library.unt.edu/web/20130305101310im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Study Chair: | Linda Gail Bekker, MBChB, FCP, PhD | Department of Medicine, University of Cape Town |
Principal Investigator: | James McIntyre, MBChB, MRCOG | University of the Witwatersrand and Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital |
![](https://webarchive.library.unt.edu/web/20130305101310im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
Publications:
Responsible Party: | James McIntyre, CIPRA SA |
ClinicalTrials.gov Identifier: | NCT00096681 History of Changes |
Other Study ID Numbers: | CIPRA-SA Project 3A, U19AI053217, CIPRA, Project 3A |
Study First Received: | November 12, 2004 |
Results First Received: | January 14, 2011 |
Last Updated: | February 17, 2011 |
Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on March 03, 2013